Search Within

Heather J Dials

Formats
  1. Meeting Abstract (7)
  2. Journal Article (2)
Groups
  1. Advanced Practice Providers (9)
  2. Nursing (9)
  3. Department of Medicine (6)
  4. Sarcoma Service (6)
  5. Solid Tumor Oncology Division (6)
  6. Biostatistics Service (4)

More Groups

People
  1. Gary Schwartz (9)
  2. Mark Dickson (6)
  3. Richard Carvajal (5)
  4. Lauren Cane (4)
  5. Manish Shah (4)
  6. Mithat Gonen (4)

More People

Years
  1. 2011 (1)
  2. 2010 (3)
  3. 2009 (2)
  4. 2008 (1)
  5. 2007 (2)
Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer Chemotherapy and Pharmacology (1)
  3. Investigational New Drugs (1)
Publishers
  1. American Society of Clinical Oncology (7)
  2. Springer (2)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
    Journal Article

    Dickson, M. A.; Rathkopf, D. E.; Carvajal, R. D.; Grant, S.; Roberts, J. D.; Reid, J. M.; Ames, M. M.; McGovern, R. M.; Lefkowitz, R. A.; Gonen, M.; more...
    Investigational New Drugs (2011)

    Fulltext@MSK | Save
  • Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer
    Meeting Abstract

    Schwartz, G. K.; Dickson, M. A.; Callahan, L. A.; Darby, C. H.; Llorente, M.; Cao, Y.; Dials, H. J.; Miller, L. L.; Miao, H. H.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors
    Meeting Abstract

    Dickson, M. A.; Rathkopf, D. E.; Grant, S.; Roberts, J. D.; Reid, J. M.; Ames, M. M.; McGovern, R. M.; Gonen, M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Journal Article

    Dickson, M. A.; Shah, M. A.; Rathkopf, D.; Tse, A.; Carvajal, R. D.; Wu, N.; Lefkowitz, R. A.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Cancer Chemotherapy and Pharmacology (2010)

    Fulltext@MSK | Save
  • A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Meeting Abstract

    Schwartz, G. K.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol
    Meeting Abstract

    Dickson, M. A.; Carvajal, R. D.; Shah, M.; Tse, A. N.; Dials, H.; Cane, L. M.; Schwartz, G. K.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase I study of FOLFOX administered with flavopiridol (F) in patients with refractory solid tumors
    Meeting Abstract

    Dickson, M. A.; Carvajal, R. D.; Shah, M. A.; Cane, L. M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
    Meeting Abstract

    O'Dwyer, P. J.; LoRusso, P.; DeMichele, A.; Gupta, V.; Barbi, A.; Dials, H.; Chen, I.; Courtney, R.; Wilner, K.; Schwartz, G. K.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Pharmacokinetics (PK) of split-dose flavopiridol (F) administered with CPT-11 (CPT) and cisplatin (Cis)
    Meeting Abstract

    Carvajal, R. D.; Tse, A.; Wu, N.; Gonen, M.; Lefkowitz, R.; Dials, H.; Barbi, A.; Mui, J.; Schwartz, G. K.; Shah, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save